Homotypic biomimetic coating synergizes chemo-photothermal combination therapy to treat breast cancer overcoming drug resistance

Guo, Kai; Liu, Yixuan; Tang, Lian; Shubhra, Quazi T.H.

doi:10.1016/j.cej.2021.131120

Cited by 40 publications

(18 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro studies on cytotoxicity found that the survival rates of MCF-7 and MCF-7/ADR cells in the chemotherapy-photothermal treatment group were reduced to more than 95% and 75%, respectively. The co-treatment group also showed excellent anti-tumor effects in the breast cancer model of drug-resistant mice [111]. Another study also found that inhalable PLGA porous microspheres loaded with dual drugs significantly inhibited tumor growth and metastasis in tumor-bearing mice with lung cancer in situ [130].…”

Section: Delivery To Cancer Cellsmentioning

confidence: 90%

PLGA-based drug delivery system for combined therapy of cancer: research progress

et al. 2021

Mater. Res. Express

View full text Add to dashboard Cite

In recent years, PLGA micro/nano particle drug delivery systems has been widely used in cancer treatment. According to the unique properties of PLGA, carriers of various structures are designed to keep the function of drugs or bioactive substances, ensure the effective load of molecules and improve the bioavailability of drugs in diseased parts. PLGA is one of the earliest and most commonly used biodegradable materials. It is often used for functional modification with other polymers (such as polyethylene glycol and chitosan) or other molecules (such as aptamers and ligands) to deliver various small molecule drugs (such as DOX and DTX) and bioactive macromolecules (such as proteins and nucleic acids) to improve targeting, controlled release and therapeutic properties. In this paper, the preparation methods, physical and chemical properties and medical applications of PLGA micro/nano particles are discussed. We focused on the recent research progress of the PLGA-based drug carrier system in tumor combination therapy.

show abstract

Section: Delivery To Cancer Cellsmentioning

confidence: 90%

PLGA-based drug delivery system for combined therapy of cancer: research progress

et al. 2021

Mater. Res. Express

View full text Add to dashboard Cite

show abstract

“…PTT is a minimally invasive and specifically targeted anticancer therapy applying photothermal therapeutic agents (PTA) and NIR laser to kill cancer cells . As a promising strategy for anticancer therapy, PTT has caught much attention in the field of anticancer therapy. − Recent investigations indicate that PTT would overcome MDR by enhancing drug release as well retention and suppressing P-gp expression. , Combined with chemotherapy or CDT, PTT shows a great potential in the reversal of drug resistance in anticancer treatment. − For example, a novel photothermally controlled drug release system (AuNP@mSiO 2 -DOX-FA) was constructed for increasing the drug loading for chemophotothermal therapy of MDR in breast cancer. The gold nanoparticles are triggered by NIR laser to produce hyperthermia effects for DOX release, leading to chemophotothermal therapy for overcoming MDR in cancer …”

Section: Ferroptosis Nanotherapeutics Combined With Other Therapeutic...mentioning

confidence: 99%

Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment

Zhu

Meng

Wang

et al. 2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Ferroptosis, characterized by iron-dependent lipid reactive oxygen species (ROS) accumulation, is non-apoptotic programmed cell death highly relevant to tumor development. It was found to manipulate oncogenes and resistant mutations of cancer cells via lipid metabolism pathways converging on phospholipid glutathione peroxidase (GPX4) that squanders lipid peroxides (L-OOH) to block the iron-mediated reactions of peroxides, thus rendering resistant cancer cells vulnerable to ferroptotic cell death. By accumulating ROS and lipid peroxidation (LPO) products to lethal levels in tumor microenvironment (TME), ferroptosis-driven nanotherapeutics show a superior ability of eradicating aggressive malignancies than traditional therapeutic modalities, especially for the drug-resistant tumors with high metastasis tendency. Moreover, Fenton reaction, inhibition of GPX-4, and exogenous regulation of LPO are three major therapeutic strategies to induce ferroptosis in cancer cells, which were generally applied in ferroptosis-driven nanotherapeutics. In this review, we elaborate current trends of ferroptosisdriven nanotherapeutics to reverse drug resistance of tumors in anticancer fields at the intersection of cancer biology, materials science, and chemistry. Finally, their challenges and perspectives toward feasible translational studies are spotlighted, which would ignite the hope of anti-resistant cancer treatment.

show abstract

“…Upon 808-nm laser irradiation (1.5 W/cm 2 ), the local temperature remarkably increased from 33 °C to 75 °C within 10 min in vitro and approximately 89.6% of DOX at pH 5.5 was released within 120 h (Chen et al., 2021 ). Recently, to overcome chemoresistance in breast cancer, an elaborate dual-target and multirelease smart DDS co-capsulating DOX, Mcl-1-siRNA and photothermal iron-oxide NPs (ICG covalently attached to IO) in the PLGA-chitosan cores, was finally cloaked with MCF-7 CM ( Figure 6(a) ) (Guo et al., 2022 ). The greater and faster release profile of DOX (∼83%) and Mcl-1-siRNA (∼71%) was attributed to the high solubility of chitosan and increased hydrolysis of PLGA at pH 5.5 combined with laser irradiation ( Figure 6(b,c) ).…”

Section: Application Of Cm@plga Nanoplatformsmentioning

confidence: 99%

Section: Application Of Cm@plga Nanoplatformsunclassified

Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application

et al. 2022

View full text Add to dashboard Cite

The emerging cell membrane (CM)-camouflaged poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) (CM@PLGA NPs) have witnessed tremendous developments since coming to the limelight. Donning a novel membrane coat on traditional PLGA carriers enables combining the strengths of PLGA with cell-like behavior, including inherently interacting with the surrounding environment. Thereby, the in vivo defects of PLGA (such as drug leakage and poor specific distribution) can be overcome, its therapeutic potential can be amplified, and additional novel functions beyond drug delivery can be conferred. To elucidate the development and promote the clinical transformation of CM@PLGA NPs, the commonly used anucleate and eukaryotic CMs have been described first. Then, CM engineering strategies, such as genetic and nongenetic engineering methods and hybrid membrane technology, have been discussed. The reviewed CM engineering technologies are expected to enrich the functions of CM@PLGA for diverse therapeutic purposes. Third, this article highlights the therapeutic and diagnostic applications and action mechanisms of PLGA biomimetic systems for cancer, cardiovascular diseases, virus infection, and eye diseases. Finally, future expectations and challenges are spotlighted in the concept of translational medicine.

show abstract

Homotypic biomimetic coating synergizes chemo-photothermal combination therapy to treat breast cancer overcoming drug resistance

Cited by 40 publications

References 55 publications

PLGA-based drug delivery system for combined therapy of cancer: research progress

PLGA-based drug delivery system for combined therapy of cancer: research progress

Ferroptosis-Driven Nanotherapeutics to Reverse Drug Resistance in Tumor Microenvironment

Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application

Contact Info

Product

Resources

About